FcRn Blockers Go Head-to-Head in Myasthenia Gravis Trial

(MedPage Today) — The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting treatments for generalized myasthenia gravis (gMG) in adults.
The phase IIIb study is designed to…